Myeloproliferative Neoplasms

Daniel DeAngelo MD, PhD, discusses the incorporation of JAK inhibitors into the myelofibrosis treatment paradigm.

Daniel J. DeAngelo MD, PhD, discusses the potential role for INCA033989 as a disease-modifying therapy in CALR type 1–mutated myelofibrosis.

Idoroenyi Amanam, MD, discusses JAK inhibitor–associated AE management and considerations for the future use of stem cell transplant in myelofibrosis.

Idoroenyi Amanam, MD, discusses characteristics that make patients with myelofibrosis most likely to derive benefit from certain JAK inhibitors.

Tapotoclax showed manageable safety, and it reduced bone marrow blasts and transfusion dependence in MDS after HMAs.

The FDA has granted orphan drug designation to tebapivat for the treatment of myelodysplastic syndromes.

Pacritinib led to improved hematologic outcomes and overall survival in real-world patients with myelofibrosis.

Peter Abdelmessieh, DO, MSC, discusses the phase 1 trial testing the combination of talazoparib and pacritinib in myeloproliferative neoplasms.

Imetelstat sustained red blood cell (RBC) transfusion independence in patients with RBC transfusion–dependent lower-risk myelodysplastic syndrome.

Sergio A. Giralt, MD, discusses how to determine transplant eligibility and the evolving role of transplant for patients with myelodysplastic syndromes.

Michael R. Grunwald, MD, FACP, discusses the characteristics of patients with polycythemia vera enrolled in the REVEAL study and limitations of the study.

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2024.

Idoroenyi Amanam, MD, discusses adverse effects associated with JAK inhibitors in myelofibrosis.

Guillermo Garcia-Manero, MD, discusses the investigation of luspatercept dose levels in patients with low-risk myelodysplastic syndrome who require red blood cell transfusions.

Areej El-Jawahri, MD, discusses a trial investigating a palliative oncology care model for patients with AML and MDS receiving nonintensive therapy.

Michael R. Grunwald, MD, discusses findings from a real-world observational study of risk factors related to disease progression in polycythemia vera.

Aaron Gerds, MD, discusses clinical implications and areas of unmet need for patients with low- or intermediate-1–risk myelofibrosis.

In case you missed any, below is a recap of every OncLive On Air episode that aired in July 2024.

The National Comprehensive Cancer Network has issued category 1 and 2A recommendations for imetelstat as therapy for symptomatic anemia in patients with lower-risk MDS.

Justin M. Watts, MD, discusses the design and purpose of a phase 1 trial evaluating INCB057643 in myelofibrosis and other advanced myeloid neoplasms.

Tycel Phillips, MD, discusses the evolution of treatment for patients with myelodysplastic syndromes, highlighting the future of this treatment paradigm.

Justin M. Watts, MD, discusses phase 1 efficacy and safety data for the oral BET inhibitor INCB057643 in advanced myelofibrosis.

The FDA has placed a partial clinical hold on a trial evaluating seclidemstat plus azacitidine in myelodysplastic syndromes or chronic myelomonocytic leukemia.

Aaron Gerds, MD discusses updated efficacy findings from the prospective randomized phase 3 MANIFEST-2 trial.

Rebecca Klisovic, MD, discusses the early use of JAK inhibitors to treat younger patients with low-risk, newly diagnosed myelofibrosis.

Mikkael A. Sekeres, MD, discusses a subgroup analysis of treatment with imetelstat in patients with low-to intermediate-1–risk myelodysplastic syndrome.

Anthony M. Hunter, MD, discusses challenges associated with ruxolitinib-based toxicities in patients with myelofibrosis.

Aaron Gerds, MD, discusses progression data for patients with low- or intermediate-1–risk myelofibrosis in the MOST trial.

Mikkael A. Sekeres, MD, discusses the FDA approval of imetelstat for patients with low- to intermediate-1–risk MDS, highlighting data from a subanalysis.

Tycel Phillips, MD, highlights key takeaways in NHL, MDS, and myelofibrosis from an OncLive State of the Science Summit on hematology.